Company: PTHS
Filing Date: 2025-05-09
Form Type: PREM14C
Source: 0001140361-25-018219
Chunk: 149

Company: Pelthos Therapeutics Inc.
Filing Date: 2025-05-09
Form: PREM14C
Chunk 149
---
 and other claims challenging inventorship of LNHC’s or its licensors’ ownership of its owned or in-licensed patents, trade secrets or other intellectual property. If LNHC or its licensors fail in defending any such claims, in addition to paying monetary damages, LNHC may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, intellectual property that is important to its systems, including its software, workflows, consumables and reagents. Even if LNHC is successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees, and certain partners may defer engaging with LNHC until the particular dispute is resolved. Any of the foregoing could have a material adverse effect on LNHC’s business, financial condition, results of operations and prospects.

If LNHC is unable to protect the confidentiality of its information and its trade secrets, the value of its technology could be materially and adversely affected and its business could be harmed.

LNHC relies on trade secrets and confidentiality agreements to protect its unpatented know-how, technology and other proprietary information, including parts of its technology platform, and to maintain its competitive position. However, trade secrets and know-how can be difficult to protect. In addition to pursuing patents on its technology,**

<div align='center'>82</div>

#### TABLE OF CONTENTS
**LNHC takes steps to protect its intellectual property and proprietary technology by entering into agreements, including confidentiality agreements, non-disclosure agreements and intellectual property assignment agreements, with its employees, consultants, academic institutions, corporate partners and, when needed, its advisers. However, LNHC cannot be certain that such agreements have been entered into with all relevant parties, and LNHC cannot be certain that its trade secrets and other confidential proprietary information will not be disclosed or that competitors will not otherwise gain access to its trade secrets or independently develop substantially equivalent information and techniques. For example, any of these parties may breach the agreements and disclose LNHC’s proprietary information, including its trade secrets, and LNHC may not be able to obtain adequate remedies for such breaches. Such agreements may not be enforceable or may not provide meaningful protection for LNHC’s trade secrets or other proprietary information in the event of unauthorized use or disclosure or other breaches of the agreements, and LNHC may not be able to prevent such unauthorized disclosure, which could adversely impact its ability to establish or maintain a competitive advantage in the market. If LNHC is required to assert its rights against such party, it could result in significant cost and distraction.

Monitoring